Displaying 1 - 15 of 15
FTC Staff Issues FY 2017 Report on Branded Drug Firms' Patent Settlements with Generic Competitors
Date
According to a new FTC staff report , the total number of final Hatch-Waxman patent settlements entered by pharmaceutical companies in FY 2017 was close to the record high in FY 2016. Despite the high...
Pharmaceutical Agreement Filing Procedures Updated
Date
The Federal Trade Commission is modernizing the process for filing agreements under the Medicare Prescription Drug, Modernization, and Improvements Act of 2003, or MMA, by requiring electronic filing...
FTC Staff Issues FY 2016 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
Date
A new Federal Trade Commission staff report found that, despite a considerable increase in the total number of final Hatch-Waxman patent settlements in FY 2016, significantly fewer settlements...
FTC Staff Issues FY 2015 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors
Date
The number of reverse-payment patent settlements entered into by pharmaceutical companies in fiscal year 2015 declined from fiscal year 2014, marking a second annual decrease in such settlements...
FTC Report on Drug Patent Settlements Shows Potential Pay-for-Delay Deals Decreased Substantially in the First Year Since Supreme Court’s Actavis Decision
Date
Pharmaceutical companies entered into substantially fewer potential pay-for-delay patent dispute settlements in fiscal year 2014, according to a new FTC staff report . The report summarizes data on...
Bristol-Myers Squibb to Pay $2.1 Million Penalty for Failure to Disclose Agreement Involving Substantial Payments to Delay Entry of a Generic Version of the Drug Plavix
Date
Drug maker Bristol-Myers Squibb Company (BMS) will pay $2.1 million – the largest fine allowed by law – for failing to inform the Federal Trade Commission of agreements reached with Apotex, Inc...
FTCs Bureau of Competition Issues FY 2007 Summary of Pharmaceutical Company Settlement Agreements
Date
The Federal Trade Commission’s Bureau of Competition today issued a summary of agreements filed with the agency in fiscal year 2007 (ending September 30, 2007) by generic and branded drug...
Bureau of Competition Issues FY 2006 Summary of Pharmaceutical Company Settlement Agreements
Date
Shows Substantial Increase in the Number of Settlements Involving a Payment to the Generic and a Restriction on Generic Entry The Federal Trade Commission’s Bureau of Competition today issued a...
Bureau of Competition Issues FY 2005 Summary of Pharmaceutical Company Settlement Agreements
Date
The Federal Trade Commission’s Bureau of Competition today issued a summary of agreements filed with the Commission in fiscal year 2005 (ending September 30, 2005) by generic and branded drug...
Displaying 1 - 15 of 15